Biotech Behind Oxford’s Coronavirus Vaccine Welcomes AZ’s Big Pharma 'Muscle'

Vaccitech Hails Partner's ‘Aggressive’ Trial Design

The University of Oxford spin-out is backing its academic partners to succeed against COVID-19 – but must also look to its own commercial future using the same adenovirus platform.

Vaccitech
Spun out in 2016, Vaccitech has co-developed with Oxford the adenovirus platform used in the COVID-19 vaccine candidate

AstraZeneca PLC has come on board as a new big pharma partner to help the University of Oxford realise its hugely ambitious plans to have its COVID-19 vaccine ready by September.

The UK-headquartered firm announced on 30 April that it had accepted the challenge to lead late-stage development of the adenovirus-based...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip